Sat.Oct 19, 2024

article thumbnail

ECG Blog #452 — Is this Wide QRS Rhythm VT?

Ken Grauer, MD

The patient whose ECG is shown in Figure-1 — presented with acute dyspnea and hypotension. QUESTION: In Figure-1 — Is the rhythm VT? — How certain are you of your answer? Figure-1: The initial ECG in today's case. ( To improve visualization — I've digitized the original ECG using PMcardio ). == MY Thoughts on the ECG in Figure-1: Although at first glance, the ECG in Figure-1 appears to be wide — this is a false initial impression!

Blog 112
article thumbnail

Patients with Major Depressive Disorder Have Increased Triglyceride Levels

HCPLive

A new meta-analysis found elevated triglyceride levels in patients with major depressive disorder, potentially explaining the link between depression and cardiovascular risks.

59
article thumbnail

Rationale and design of OPT-RATE AF: A randomized clinical trial of increased physiologic pacing rates in heart failure with preserved ejection fraction

The American Journal of Cardiology

Publication date: Available online 18 October 2024 Source: The American Journal of Cardiology Author(s): Evan Czulada, Jamal D. Smith, Paul Kolm, Brototo Deb, Sarahfaye F. Dolman, Nebu Alexander, Ryan A. Braun, Rajiv A. Kabadi, William S.

article thumbnail

SKYLINE: AGTC-501 Reports Positive 24-Month Data in X-Linked Retinitis Pigmentosa

HCPLive

The 24-month data showed a notable response rate in study eyes treated with a high dose of AGTC-501, with a generally safe and tolerable clinical profile.

59
article thumbnail

Study Identifies Approaches to Address Patient Fears Regarding JAK Inhibitor Safety

HCPLive

Given the distrust some patients with conditions such as alopecia areata and psoriasis have regarding JAK inhibitors, this analysis highlights several approaches to such concerns.

52
article thumbnail

Geographic Disparities in Liver-Related Mortality Suggest Inequitable Access to Liver Transplant

HCPLive

Liver-related mortality in the US increased by nearly 20% from 2018, with lower transplant rates observed in states with the greatest mortality.

article thumbnail

ARCHER: ANX007 Mitigates Visual Acuity Loss in Geographic Atrophy

HCPLive

In the Phase 2 ARCHER trial, ANX007 protected against visual acuity loss and remained well-tolerated for patients with geographic atrophy.

59
article thumbnail

Diana V. Do, MD: 3-Year PHOTON Data on Aflibercept 8 mg for DME

HCPLive

At AAO 2024, Do describes the durable vision gains and anatomic improvements achieved with aflibercept 8 mg for DME over 3 years of the PHOTON trial.

52